

Pedro M Machado Frcp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6420729/publications.pdf>

Version: 2024-02-01

268
papers

11,210
citations

44069

48
h-index

34986

98
g-index

306
all docs

306
docs citations

306
times ranked

10352
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.9	1,220
2	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.9	908
3	Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 47-53.	0.9	589
4	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.9	496
5	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
6	MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 65-77.	10.2	256
7	Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1465-1470.	0.9	244
8	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 8-13.	0.9	223
9	Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. <i>Brain</i> , 2021, 144, 682-693.	7.6	221
10	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.9	204
11	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1016-1023.	0.9	188
12	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 30-39.	0.9	183
13	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	3.9	172
14	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1550-1558.	0.9	171
15	Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1539-1540.	0.9	159
16	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
17	Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 809-816.	0.9	148
18	Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt – a national health survey. <i>RMD Open</i> , 2016, 2, e000166.	3.8	133

#	ARTICLE	IF	CITATIONS
19	HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1930-1936.	0.9	131
20	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.9	130
21	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1558-1566.	0.9	127
22	MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 369-373.	0.9	126
23	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	3.8	121
24	Rheumatic disease and COVID-19: epidemiology and outcomes. <i>Nature Reviews Rheumatology</i> , 2021, 17, 71-72.	8.0	120
25	Disease specificity of autoantibodies to cytosolic 5â€²-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 696-701.	0.9	116
26	MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1486-1493.	0.9	103
27	Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. <i>Nature Communications</i> , 2017, 8, 1859.	12.8	102
28	Update on outcome assessment in myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 303-318.	8.0	100
29	Targeting protein homeostasis in sporadic inclusion body myositis. <i>Science Translational Medicine</i> , 2016, 8, 331ra41.	12.4	99
30	Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 699-705.	0.9	98
31	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Neurology</i> , The, 2019, 18, 834-844.	10.2	91
32	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1628-1639.	0.9	89
33	MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 2002-2005.	0.9	87
34	Response to: â€œCorrespondence on â€œFactors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registryâ€™â€™ by Mulhearn <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e116-e116.	0.9	87
35	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
36	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 996-1002.	0.9	81

#	ARTICLE	IF	CITATIONS
37	Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 422-432.	0.9	75
38	Cytosolic 5â€²-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 862-868.	0.9	71
39	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, 2615-2628.	1.9	69
40	Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 15-24.	0.9	68
41	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1386-1388.	0.9	67
42	Association of Race and Ethnicity With COVIDâ€19 Outcomes in Rheumatic Disease: Data From the COVIDâ€19 Global Rheumatology Alliance Physician Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 374-380.	5.6	66
43	A stratified model for health outcomes in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1758-1764.	0.9	65
44	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001450.	3.8	64
45	Longitudinal observational study of sporadic inclusion body myositis: Implications for clinical trials. <i>Neuromuscular Disorders</i> , 2013, 23, 404-412.	0.6	63
46	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	0.9	59
47	COVID-19 vaccination and Guillain-BarrÃ© syndrome: analyses using the National Immunoglobulin Database. <i>Brain</i> , 2023, 146, 739-748.	7.6	57
48	Prevalence and social burden of active chronic low back pain in the adult Portuguese population: results from a national survey. <i>Rheumatology International</i> , 2016, 36, 183-197.	3.0	55
49	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 518-526.	0.9	54
50	Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10. <i>Journal of Rheumatology</i> , 2011, 38, 1502-1506.	2.0	52
51	Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. <i>Rheumatology International</i> , 2021, 41, 1021-1036.	3.0	52
52	How to measure disease activity in axial spondyloarthritis?. <i>Current Opinion in Rheumatology</i> , 2011, 23, 339-345.	4.3	51
53	Brief Report: Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional Câ€Reactive Protein Level Is Below the Limit of Detection or If Highâ€Sensitivity Câ€Reactive Protein Is Used: An Analysis in the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2015, 67, 408-413.	5.6	50
54	Cross-cultural validation of the Educational Needs Assessment Tool in RA in 7 European countries. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 110.	1.9	49

#	ARTICLE	IF	CITATIONS
55	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.9	49
56	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. <i>Rheumatology</i> , 2021, 60, 4778-4789.	1.9	44
57	Immune Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology</i> , 2017, 69, 1090-1099.	5.6	41
58	Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database. <i>Arthritis Care and Research</i> , 2019, 71, 1317-1325.	3.4	41
59	Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. <i>Neurobiology of Aging</i> , 2016, 47, 218.e1-218.e9.	3.1	40
60	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	3.9	40
61	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. <i>Rheumatology</i> , 2022, 61, S1143-S1150.	1.9	40
62	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	3.9	38
63	Validation of the educational needs assessment tool as a generic instrument for rheumatic diseases in seven European countries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2122-2129.	0.9	37
64	Community exercise is feasible for neuromuscular diseases and can improve aerobic capacity. <i>Neurology</i> , 2019, 92, e1773-e1785.	1.1	37
65	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706.	0.9	37
66	British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2022, 61, 1760-1768.	1.9	37
67	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e109-e109.	0.9	35
68	Recommendations for acquisition and interpretation of MRI of the spine and sacroiliac joints in the diagnosis of axial spondyloarthritis in the UK. <i>Rheumatology</i> , 2019, 58, 1831-1838.	1.9	35
69	The ASAS-OMERACT core domain set for axial spondyloarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1342-1349.	3.4	35
70	Update in inclusion body myositis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 763-771.	4.3	34
71	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	3.8	34
72	The Value of Magnetic Resonance Imaging and Ultrasound in Undifferentiated Arthritis: A Systematic Review. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 31-37.	2.2	33

#	ARTICLE	IF	CITATIONS
73	The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. <i>Rheumatology</i> , 2021, 60, 353-358.	1.9	32
74	Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 293-303.	0.9	32
75	Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 803-815.	0.9	31
76	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 145-150.	0.9	30
77	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>Lancet Rheumatology</i> , The, 2022, 4, e237-e240.	3.9	30
78	Is it time to replace BASDAI with ASDAS?. <i>Nature Reviews Rheumatology</i> , 2013, 9, 388-390.	8.0	29
79	Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 711-728.	3.3	29
80	Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 88.	2.7	28
81	Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000430.	3.8	28
82	Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101657.	3.3	28
83	The Use of Analgesic and Other Pain Relief Drugs to Manage Chronic Low Back Pain: Results from a National Survey. <i>Pain Practice</i> , 2017, 17, 353-365.	1.9	26
84	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. <i>Frontiers in Medicine</i> , 2018, 5, 40.	2.6	26
85	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40.	0.9	26
86	EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology. <i>Acta Reumatológica Portuguesa</i> , 2015, 40, 110-24.	0.2	26
87	Performance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review. <i>Rheumatology</i> , 2019, 58, 1955-1965.	1.9	25
88	Capturing Patient-Reported Outcomes During the COVID-19 Pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey. <i>Arthritis Care and Research</i> , 2020, 72, 871-873.	3.4	25
89	Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis. <i>Neurology</i> , 2021, 96, e1595-e1607.	1.1	25
90	SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e481-e488.	3.9	25

#	ARTICLE	IF	CITATIONS
91	Anti-TNF and new bone formation in ankylosing spondylitis - the controversy continues. Arthritis and Rheumatism, 2013, 65, n/a-n/a.	6.7	24
92	The diagnostic role of diffusional kurtosis imaging in glioma grading and differentiation of gliomas from other intra-axial brain tumours: a systematic review with critical appraisal and meta-analysis. Neuroradiology, 2020, 62, 791-802.	2.2	23
93	MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2022, 81, 1243-1251.	0.9	22
94	LB0002â€¦COVID-19 VACCINE SAFETY IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASE. Annals of the Rheumatic Diseases, 2021, 80, 199-200.	0.9	21
95	OP0008â€¦DEVELOPMENT AND VALIDATION OF AN ALTERNATIVE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE WHEN PATIENT GLOBAL ASSESSMENT IS UNAVAILABLE. Annals of the Rheumatic Diseases, 2020, 79, 6-6.	0.9	21
96	Biologics for treating axial spondyloarthritis. Expert Opinion on Biological Therapy, 2018, 18, 641-652.	3.1	20
97	Measuring Spinal Mobility Using an Inertial Measurement Unit System: A Validation Study in Axial Spondyloarthritis. Diagnostics, 2020, 10, 426.	2.6	20
98	Treat-to-target in axial spondyloarthritis: gold standard or foolsâ€™ gold?. Current Opinion in Rheumatology, 2019, 31, 344-348.	4.3	19
99	Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Annals of the Rheumatic Diseases, 2013, 72, 1104-1107.	0.9	18
100	Ongoing Developments in Sporadic Inclusion Body Myositis. Current Rheumatology Reports, 2014, 16, 477.	4.7	18
101	Sporadic inclusion body myositis. Current Opinion in Neurology, 2014, 27, 591-598.	3.6	18
102	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2023, 82, 763-772.	0.9	18
103	The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiology of Aging, 2015, 36, 1766.e1-1766.e3.	3.1	16
104	Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-Î³ autoantibodies in adult patients with myositis. Arthritis Research and Therapy, 2018, 20, 117.	3.5	16
105	Selecting men for bone densitometry: performance of osteoporosis risk assessment tools in Portuguese men. Osteoporosis International, 2010, 21, 977-983.	3.1	15
106	Measurements, composite scores and the art of â€œcutting-offâ€™. Annals of the Rheumatic Diseases, 2016, 75, 787-790.	0.9	15
107	Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 854-862.	1.9	15
108	Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, 220.	3.5	14

#	ARTICLE	IF	CITATIONS
109	Frequency and circumstances of falls in people with inclusion body myositis: a questionnaire survey to explore falls management and physiotherapy provision. <i>Physiotherapy</i> , 2014, 100, 61-65.	0.4	14
110	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. <i>RMD Open</i> , 2016, 2, e000240.	3.8	14
111	Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 935-942.	0.9	14
112	Classification Criteria in Axial Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 259-274.	1.9	14
113	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001549.	3.8	14
114	Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. <i>Clinical Rheumatology</i> , 2010, 29, 629-635.	2.2	13
115	How to investigate: Early axial spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101427.	3.3	13
116	Axial Spondyloarthritis: Mimics and Pitfalls of Imaging Assessment. <i>Frontiers in Medicine</i> , 2021, 8, 658538.	2.6	13
117	Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. <i>Current Opinion in Rheumatology</i> , 2021, 33, 111-116.	4.3	12
118	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	0.9	12
119	Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 998-1005.	0.9	12
120	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 54-58.	2.2	11
121	Association Between Disease Activity and Disability in Early Axial Spondyloarthritis: Results From a Prospective Observational Study of Inflammatory Back Pain. <i>Arthritis Care and Research</i> , 2022, 74, 768-775.	3.4	11
122	COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: "Correspondence on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry" by Gianfrancesco et al. <i>Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials: a real-world district general hospital experience</i> by K. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-218713.	0.9	11
123	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2021, 8, 273-288.	2.3	11
124	Who are the young professionals working in the field of rheumatology in Europe and what are their needs? An EMEUNET (EMerging Eular NETwork) survey. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1432-1433.	0.9	10
125	Validity and reliability of a sensor-based electronic spinal mobility index for axial spondyloarthritis. <i>Rheumatology</i> , 2020, 59, 3415-3423.	1.9	10
126	Conducting research in a pandemic: The power of social media. <i>European Journal of Rheumatology</i> , 2020, 7, S85-S88.	0.6	10

#	ARTICLE	IF	CITATIONS
127	Sporadic inclusion body myositis: an unsolved mystery. <i>Acta Reumatológica Portuguesa</i> , 2009, 34, 161-82.	0.2	10
128	EpiReumaPt: how to perform a national population based study - a practical guide. <i>Acta Reumatológica Portuguesa</i> , 2015, 40, 128-36.	0.2	10
129	Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. <i>Rheumatology</i> , 2021, 60, 638-648.	1.9	9
130	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	2.0	9
131	EULAR points to consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 760-767.	0.9	9
132	Experience with telemedicine amongst rheumatology clinicians during the COVID-19 pandemic: an international survey. <i>Rheumatology Advances in Practice</i> , 0, , .	0.7	9
133	Genetic advances in sporadic inclusion body myositis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 586-594.	4.3	8
134	Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis. <i>Muscle and Nerve</i> , 2019, 60, 161-168.	2.2	8
135	Determining factors related to impaired spinal and hip mobility in patients with axial spondyloarthritis: longitudinal results from the DESIR cohort. <i>RMD Open</i> , 2020, 6, e001356.	3.8	8
136	Response to: "Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis" by Györfi <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e88-e88.	0.9	8
137	Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001899.	3.8	8
138	Overview of the ECAL off-detector electronics of the CMS experiment. <i>IEEE Transactions on Nuclear Science</i> , 2005, 52, 1918-1924.	2.0	7
139	Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by van Vollenhoven <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e178-e178.	0.9	7
140	The impact of COVID-19 on rheumatology training" results from the COVID-19 Global Rheumatology Alliance trainee survey. <i>Rheumatology Advances in Practice</i> , 2022, 6, rak001.	0.7	7
141	COVID-19-Related Outcomes in Primary Mitochondrial Diseases. <i>Neurology</i> , 2022, 98, 576-582.	1.1	7
142	Longitudinal Changes in MRI Muscle Morphometry and Composition in People With Inclusion Body Myositis. <i>Neurology</i> , 2022, 99, .	1.1	7
143	An overview of the Clear-PEM breast imaging scanner. , 2008, , .		6
144	Role of diffusional kurtosis imaging in grading of brain gliomas: a protocol for systematic review and meta-analysis. <i>BMJ Open</i> , 2018, 8, e025123.	1.9	6

#	ARTICLE	IF	CITATIONS
145	No relationship between bone mineral density and syndesmophyte formation at the same level in the lumbar spine of patients with radiographic axial Spondyloarthritis. <i>RMD Open</i> , 2020, 6, e001391.	3.8	6
146	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1110-1115.	0.9	6
147	Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. <i>RMD Open</i> , 2021, 7, e001685.	3.8	6
148	Recent advances in managing axial spondyloarthritis. <i>F1000Research</i> , 2020, 9, 697.	1.6	6
149	Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. <i>ACR Open Rheumatology</i> , 2022, 4, 128-133.	2.1	6
150	Value of imaging to guide interventional procedures in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001864.	3.8	6
151	Arthritis and X-linked agammaglobulinemia. <i>Acta Reumatológica Portuguesa</i> , 2008, 33, 464-7.	0.2	6
152	Measuring change in inclusion body myositis: clinical assessments versus imaging. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 404-413.	0.8	6
153	Performance of referral strategies for spondyloarthritis: a population-based nationwide study. <i>Rheumatology</i> , 2019, 58, 1086-1094.	1.9	5
154	Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: "Correspondence on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry" by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases" by Giollo et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e223-e223.	0.9	5
155	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. <i>RMD Open</i> , 2021, 7, e001728.	3.8	5
156	The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis. <i>Acta Reumatológica Portuguesa</i> , 2018, 43, 52-60.	0.2	5
157	Experimental validation and performance analysis of the clear-PEM data acquisition electronics. , 2008, , .		4
158	The Value of Conventional Radiographs in Undifferentiated Arthritis: A Systematic Review. <i>Journal of rheumatology Supplement, The</i> , 2011, 87, 26-30.	2.2	4
159	Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. <i>Arthritis Research and Therapy</i> , 2016, 18, 156.	3.5	4
160	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , 2021, 7, e001818.	3.8	4
161	Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update. <i>Acta Reumatológica Portuguesa</i> , 2010, 35, 95-8.	0.2	4
162	Predictors of response to TNF blockers in patients with polyarticular psoriatic arthritis. <i>Acta Reumatológica Portuguesa</i> , 2017, 42, 55-65.	0.2	4

#	ARTICLE	IF	CITATIONS
163	The role of imaging in evaluating patients with idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 114, 74-81.	0.8	4
164	Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNF±. <i>Joint Bone Spine</i> , 2009, 76, 508-513.	1.6	3
165	Sacroiliac joint radiographic progression “ speed and determinants. <i>Nature Reviews Rheumatology</i> , 2016, 12, 380-382.	8.0	3
166	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 20-27.	2.0	3
167	Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa015.	0.7	3
168	Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry” by Sparks <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e158-e158.	0.9	3
169	Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey. <i>Frontiers in Medicine</i> , 2021, 8, 779975.	2.6	3
170	Correspondence on “Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment”™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e183-e183.	0.9	3
171	On restoring data coherence in a GALS system for medical imaging. , 2010, , .		2
172	SAT0236“...Prevalence of Comorbidities and Evaluation of Their Screening in Spondyloarthritis: Results of the International Cross-Sectional ASAS-Comospa Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 743.4-744.	0.9	2
173	OP0023“...Four-year imaging outcomes in axial spondyloarthritis patients treated with certolizumab pegol, including patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. , 2017, , .		2
174	P.02Phase 2/3 study of Arimoclomol in sporadic inclusion body myositis: study design. <i>Neuromuscular Disorders</i> , 2019, 29, S41-S42.	0.6	2
175	Inhibition of interleukin-17 in axial spondyloarthritis spectrum. <i>Lancet, The</i> , 2020, 395, 6-8.	13.7	2
176	Response to: “Correspondence on “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry”™ by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.9	2
177	Response to: “Correspondence on “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry”™”™ by Rosenbaum <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.9	2
178	POS1183“...OUTCOMES OF COVID-19 INFECTION AMONG CHILDREN AND YOUNG PEOPLE WITH PRE-EXISTING RHEUMATIC AND MUSCULOSKELETAL DISEASES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 872.2-873.	0.9	2
179	FRI0317“...CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SPINE OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: FIRST ANALYSIS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY CLASSIFICATION COHORT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 749.2-750.	0.9	2
180	THUR 219“...Myopathic manifestations in haematological conditions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A31.3-A31.	1.9	2

#	ARTICLE	IF	CITATIONS
181	OPO199â€¦POINTS TO CONSIDER WHEN ANALYSING AND REPORTING COMPARATIVE EFFECTIVENESS RESEARCH WITH OBSERVATIONAL DATA IN RHEUMATOLOGY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 124-125.	0.9	2
182	Translation and cross-cultural adaptation of the ASAS Health Index and ASAS Environmental Factors Item Set into European Portuguese Language. <i>Acta Reumatolgica Portuguesa</i> , 2017, 42, 256-262.	0.2	2
183	Measuring quality of life of patients with axial spondyloarthritis for economic evaluation. <i>RMD Open</i> , 2022, 8, e001955.	3.8	2
184	Axial spondyloarthritis. <i>Medicine</i> , 2022, 50, 159-166.	0.4	2
185	FRI0291â€¦MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a TNF inhibitor:. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 412.2-412.	0.9	1
186	OPO171â€¦Achievement of Remission of Inflammation in the Spine and Sacroiliac Joints Measured by Magnetic Resonance Imaging (MRI) in Patients with Axial Spondyloarthritis, and Associations Between MRI and Clinical Remission, Over 96 Weeks of Treatment with Certolizumab Pegol. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 134.2-135.	0.9	1
187	THU0685â€¦.Asas health index for patients with spondyloarthritis: translation into portuguese, validation, and reliability. , 2017, , .		1
188	AB0868â€¦Lumbar muscles stiffness in patients with axial spondyloarthritis is altered in comparison with healthy subjects. , 2018, , .		1
189	AB0867â€¦Axial spondyloarthritis posture assessment using inertial sensors. , 2018, , .		1
190	THU0361â€¦DIAGNOSTIC PERFORMANCE OF MRI LESIONS IN THE SACROILIAC JOINTS ACCORDING TO UPDATED ASAS LESION DEFINITIONS: A CENTRAL READER ASSESSMENT OF MRI SCANS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS CLASSIFICATION COHORT. , 2019, , .		1
191	Differential Diagnoses of Inclusion Body Myositis. <i>Neurologic Clinics</i> , 2020, 38, 697-710.	1.8	1
192	OPO286â€¦CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 173.2-175.	0.9	1
193	OPO288â€¦MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 175.2-176.	0.9	1
194	POS0055â€¦SARS-COV-2 OUTBREAK IN AUTOIMMUNE DISEASES: THE EURO-COVIMID STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 233-234.	0.9	1
195	The Early History of Arimoclomol for Inclusion Body Myositis. <i>RRNMF Neuromuscular Journal</i> , 2021, 2, .	0.1	1
196	The Effect of ACTN3 and VDR Polymorphisms on Skeletal Muscle Performance in Axial Spondyloarthropathies. <i>Frontiers in Genetics</i> , 2021, 12, 688984.	2.3	1
197	FRI0202â€¦Inertial motion sensors using the vimove system is a valid method to assess spinal mobility in patients with axial spondyloarthritis. , 2018, , .		1
198	FRI0170â€¦Consensus definitions for mri lesions in the sacroiliac joints of patients with axial spondyloarthritis: first analysis from the assessments in spondyloarthritis international society (ASAS) classification cohort. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
199	THU0276â€¦MRI lesion definitions in axial spondyloarthritis: a consensus reappraisal from the assessments in spondyloarthritis international society (ASAS). , 2018, , .		1
200	OP0249â€¦The contribution of structural MRI lesions to detection of sacroiliitis in patients in the assessments in spondyloarthritis international society (ASAS) classification cohort. , 2018, , .		1
201	OP0079â€¦PRELIMINARY DEFINITION OF A POSITIVE MRI FOR STRUCTURAL LESIONS IN THE SACROILIAC JOINTS IN AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 53-54.	0.9	1
202	OP0060â€¦MACHINE LEARNING BASED BERLIN SCORING OF MAGNETIC RESONANCE IMAGES OF THE SPINE IN PATIENTS WITH ANKYLOSING SPONDYLITIS FROM THE MEASURE 1 STUDY. Annals of the Rheumatic Diseases, 2020, 79, 40-41.	0.9	1
203	OP0198â€¦A SYSTEMATIC REVIEW TO INFORM THE EULAR POINTS TO CONSIDER WHEN ANALYSING AND REPORTING COMPARATIVE EFFECTIVENESS RESEARCH WITH OBSERVATIONAL DATA IN RHEUMATOLOGY. Annals of the Rheumatic Diseases, 2020, 79, 123.2-124.	0.9	1
204	AB1083â€¦CURRENT PRACTICE AND OPINIONS ON IMAGING-GUIDED INTERVENTIONAL PROCEDURES IN RHEUMATIC AND MUSCULOSKELETAL DISEASES: INTERIM RESULTS OF A MULTINATIONAL MULTIDISCIPLINARY SURVEY TO INFORM EULAR POINTS TO CONSIDER. Annals of the Rheumatic Diseases, 2020, 79, 1830.2-1831.	0.9	1
205	Correspondence on â€œReâ€œexamining remission definitions in rheumatoid arthritis: considering the <sc>28â€œjoint</sc> Disease Activity Score, Câ€œreactive protein level and patient global assessmentâ€œby Felson et al. ACR Open Rheumatology, 2022, 4, 271-272.	2.1	1
206	Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis–December 2011 update. Acta ReumatolÃ³gica Portuguesa, 2012, 37, 40-7.	0.2	1
207	Educational needs in people with ankylosing spondylitis and psoriatic arthritis: a cross-sectional study. Clinical and Experimental Rheumatology, 2020, 38, 282-288.	0.8	1
208	The European Portuguese version of the ASAS Health Index for Patients with Spondyloarthritis: Measurement properties. Acta ReumatolÃ³gica Portuguesa, 2020, 45, 26-33.	0.2	1
209	Rituximab in rheumatology: single-centre SARS-CoV-2 infection and COVID-19 prevalence. Rheumatology Advances in Practice, 2022, 6, rrac009.	0.7	1
210	EMerging EULAR NETWORK (EMEUNET): a remarkable foundation for the future. RMD Open, 2021, 7, e001962.	3.8	1
211	Minimal Impact of the <sc>COVID</sc> â€œ19 Pandemic on Disease Activity and <sc>Healthâ€œRelated</sc> Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b <sc>Openâ€œLabel</sc> Extension Study. ACR Open Rheumatology, 0, , .	2.1	1
212	P71 A randomised, double-blinded, placebo-controlled pilot study assessing the safety and tolerability of Arimoclomol in sporadic inclusion body myositis (IBM). Neuromuscular Disorders, 2011, 21, S27.	0.6	0
213	P79 The natural history of sporadic inclusion body myositis: development of an electronic database IBM net. Neuromuscular Disorders, 2011, 21, S29.	0.6	0
214	097â€¦Valosin Containing Protein (VCP) and Myofibrillar Myopathies (MFM) genes' mutations are not associated with sporadic Inclusion Body Myositis (sIBM). Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.45-e1.	1.9	0
215	1130â€¦Clinical features and clinical course of sporadic inclusion body myositis (IBM): a prospective cohort study: IBM-net. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.101-e1.	1.9	0
216	New developments in the diagnosis and treatment of axial spondyloarthritis. Clinical Investigation, 2013, 3, 153-171.	0.0	0

#	ARTICLE	IF	CITATIONS
217	THU0283â€¦Predictive factors of response at 12 weeks in patients with ankylosing spondylitis starting biological therapies - results from the portuguese register - REUMA.PT.: Annals of the Rheumatic Diseases, 2013, 71, 251.1-251.	0.9	0
218	FRIO126â€¦The Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining the Best Calculation Method When the Conventional C-Reactive Protein (CRP) is below the Threshold of Detection - Results from the DESIR Cohort. Annals of the Rheumatic Diseases, 2014, 73, 427.1-427.	0.9	0
219	OP0133â€¦Educational Needs of Young Clinicians and Researchers Working in Field of Rheumatology â€œ Results from the Emeunet/Escet Survey. Annals of the Rheumatic Diseases, 2014, 73, 111.1-111.	0.9	0
220	Inclusion body myositis: clinical review and current practice. Clinical Practice (London, England), 2014, 11, 623-637.	0.1	0
221	SP0067â€¦How to Develop Meaningful Indices from Scratch (E.G. ASDAS). Annals of the Rheumatic Diseases, 2014, 73, 18.3-18.	0.9	0
222	OP0052â€¦Prevalence and Physical and Mental Health Patterns of Rheumatic and Musculoskeletal Diseases in Portugal: Results from Epireumapt, A National Health Survey. Annals of the Rheumatic Diseases, 2015, 74, 86.2-86.	0.9	0
223	Study design of a prospective natural history study in sporadic inclusion body myositis (sIBM). Neuromuscular Disorders, 2015, 25, S238.	0.6	0
224	OP0041â€¦MRI Inflammation and Fat Deposition Both Contribute to Syndesmophyte Formation at the Same Site: A Multi-Level Analysis in Patients with Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2015, 74, 81.2-82.	0.9	0
225	SAT0525â€¦The Use of Analgesic and Other Pain Relief Drugs To Manage Chronic Low Back Pain â€œ Results from A National Survey: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 859.2-859.	0.9	0
226	AB1069â€¦The Educational Needs of People with Spondyloarthropathies (AS and PSA): A Cross-Sectional Study: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 1267.2-1267.	0.9	0
227	Evaluating the benefits of community based aerobic training on the physical health and well-being of people with neuromuscular disease. Neuromuscular Disorders, 2017, 27, S43.	0.6	0
228	Reversible endogenous downregulation of myostatin pathway in wasting neuromuscular diseases explains challenges of anti-myostatin therapeutic approaches. Neuromuscular Disorders, 2017, 27, S97-S98.	0.6	0
229	Myostatin expression levels in neuromuscular diseases participates in anti-myostatin clinical failure. Neuromuscular Disorders, 2017, 27, S231.	0.6	0
230	FRIO126â€¦Aiming for remission according to any of the rheumatoid arthritis disease activity indices is more important for physical function than the actual choice of index: a longitudinal analysis in a clinical practice setting (meteor cohort). , 2017, , .		0
231	SAT0718-HPRâ€¦Influence of patient global assessment on the disease activity assessment in patients with rheumatoid arthritis: a meteor cross-sectional study. , 2017, , .		0
232	Translating discovery science into treatments for patients: observational cohort studies at the MRC Centre for Neuromuscular Diseases. Neuromuscular Disorders, 2018, 28, S37.	0.6	0
233	Letter to the Editor (Matters arising from published papers). Rheumatology, 2019, 59, 261-262.	1.9	0
234	Role of diffusional kurtosis imaging in grading of brain gliomas: A diagnostic test accuracy systematic review and meta-analysis. Neuro-Oncology, 2019, 21, iv12-iv12.	1.2	0

#	ARTICLE	IF	CITATIONS
235	253â€fPerformance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review. <i>Rheumatology</i> , 2019, 58, .	1.9	0
236	SAT0307â€…LONG-TERM ASSOCIATION BETWEEN DISEASE ACTIVITY MEASURED BY ASDAS AND PHYSICAL FUNCTION IN A LARGE EARLY AXIAL SPONDYLOARTHRITIS COHORT. , 2019, , .		0
237	THU0359â€…WHAT IS THE LEVEL OF AGREEMENT BETWEEN LOCAL AND CENTRAL READERS IN THE DETECTION OF ACTIVE AND STRUCTURAL LESIONS ON MRI TYPICAL OF AXIAL SPONDYLOARTHRITIS? DATA FROM THE ASAS CLASSIFICATION COHORT STUDY. , 2019, , .		0
238	PTH-123â€…Is axial spondyloarthritis in IBD different to axial spondyloarthritis without IBD?. , 2019, , .		0
239	SAT0327â€…SEGMENTAL RELATIONSHIP BETWEEN MOBILITY, STRUCTURAL DAMAGE AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
240	FR10419â€…OUTCOMES OF DOSE REDUCTION OF TNF-INHIBITORS IN AXIAL SPONDYLOARTHRITIS AT 24 MONTHS. , 2019, , .		0
241	THU0358â€…DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
242	THU0366â€…MAGNETIC RESONANCE IMAGING IN COMPARISON WITH CONVENTIONAL RADIOGRAPHY FOR DETECTION OF STRUCTURAL CHANGES TYPICAL FOR SPA â€“ DATA FROM THE ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) COHORT. , 2019, , .		0
243	PTH-122â€…Faecal calprotectinsuggests presence of gut inflammation in axial spondyloarthritis without IBD. , 2019, , .		0
244	P263â€fShould we advocate biologic dose-reduction in patients with AxSpA?. <i>Rheumatology</i> , 2020, 59, .	1.9	0
245	OPO287â€…IMMUNOMODULATORY THERAPIES FOR SEVERE FORMS OF COVID-19: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 175.1-175.	0.9	0
246	AB0674â€…RAPID ADOPTION OF TELEMEDICINE IN RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1368.3-1369.	0.9	0
247	POS0051â€…THE IMPACT OF COVID-19 ON RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 230.2-231.	0.9	0
248	POS0238â€…SICK LEAVE AND ITS PREDICTORS IN EARLY AXIAL SPONDYLOARTHRITIS: THE ROLE OF CLINICAL AND SOCIOECONOMIC FACTORS. FIVE-YEAR DATA FROM THE DESIR COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 340.2-340.	0.9	0
249	POS0952â€…RESPONSIVENESS OF SPINAL MOBILITY MEASUREMENTS IN AXIAL SPONDYLOARTHRITIS USING CONVENTIONAL AND ADVANCED METROLOGY: A PILOT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 740.1-740.	0.9	0
250	OP0047â€…IDENTIFICATION OF CLINICAL PHENOTYPES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS ACCORDING TO PERIPHERAL MUSCULOSKELETAL MANIFESTATIONS: A CLUSTER ANALYSIS IN THE INTERNATIONAL ASAS-PERSPA STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 24.2-25.	0.9	0
251	POS0052â€…PATHOPHYSIOLOGY OF ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 231-232.	0.9	0
252	Phase II Study of Arimoclomol in IBM FDA-OOPD. <i>RRNMF Neuromuscular Journal</i> , 2021, 2, .	0.1	0

#	ARTICLE	IF	CITATIONS
253	Mitochondrial disease and COVID-19: An international cohort study confirms risks and long-term outcomes. Journal of the Neurological Sciences, 2021, 429, 119358.	0.6	0
254	A cross-sectional study of memory and executive functions in patients with sporadic inclusion body myositis. Muscle and Nerve, 2021, 65, 105.	2.2	0
255	AB0866-Advanced metrology in patients with axial spondyloarthritis: lumbar or thoracic+lumbar measurements for spinal mobility assessment?. , 2018, , .		0
256	FRI0169-First validation of consensus definitions for mri lesions in the sacroiliac joint by the assessments in spondyloarthritis international society (ASAS) mri group. , 2018, , .		0
257	FRI0209-Recommendations for acquisition and considerations for interpretation of mri of the spine and sacroiliac joints in the investigation of axial spondyloarthritis in the uk. , 2018, , .		0
258	OPO247-Performance of referral strategies for spondyloarthritis: a population-based nationwide study. , 2018, , .		0
259	SAT0673-Magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review. , 2018, , .		0
260	FRI0302-WHAT IS THE IMPACT OF DISCREPANCY BETWEEN CENTRAL AND LOCAL READERS IN EVALUATION OF MRI SCANS ON THE CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS? DATA FROM THE ASAS CLASSIFICATION COHORT STUDY. Annals of the Rheumatic Diseases, 2020, 79, 740.2-741.	0.9	0
261	SAT0332-ANTIBODIES AGAINST CYTOSOLIC 5-NUCLEOTIDASE 1A IN SPORADIC INCLUSION BODY MYOSITIS: ASSOCIATION WITH CLINICAL AND MRI FEATURES. Annals of the Rheumatic Diseases, 2020, 79, 1112.1-1112.	0.9	0
262	OPO078-MAPPING FROM THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (ASDAS) TO EQ5D IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 52.1-53.	0.9	0
263	SAT0384-REPLACEMENT OF RADIOGRAPHIC SACROILITIS BY MRI STRUCTURAL LESIONS: WHAT IS THE IMPACT ON CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS IN THE ASAS CLASSIFICATION COHORT?. Annals of the Rheumatic Diseases, 2020, 79, 1140.2-1141.	0.9	0
264	Reexamining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C-reactive protein level, and patient global assessment: comment on the article by Felson et al. Arthritis Care and Research, 2022, 74, 501-502.	3.4	0
265	Development and validation of psoriatic arthritis switch quality assessment tool (PASQAL) - an outcomes measurement tool to assess the quality of biologic switch decisions in psoriatic arthritis. Acta Reumatologica Portuguesa, 2020, 45, 46-57.	0.2	0
266	Diagnostic and prognostic value of anti-cN1A antibodies in inclusion body myositis.. Clinical and Experimental Rheumatology, 2022, 40, 384-393.	0.8	0
267	Measuring change in inclusion body myositis: clinical assessments versus imaging.. Clinical and Experimental Rheumatology, 2022, 40, 404-413.	0.8	0
268	OA01-Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Rheumatology, 2022, 61, .	1.9	0